Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nebivolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | NPY1R | P25929 | 1/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nebivolol SCHEMBL866435 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL18255259 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL13762675 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL20007010 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL12375910 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL8511892 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL3909519 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL8503436 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL3791946 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL2837419 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637708-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | Novaliq GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| WO-2024133913-A9 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2025-03-20 | — | — | WO | claimed |
| WO-2024133913-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| EP-4162278-A1 | BIOMARKER IDENTIFICATION FOR IMMINENT AND/OR IMPENDING HEART FAILURE | ESN Cleer (AU) | 2023-04-12 | — | — | EP | claimed |
| US-20220056003-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2022-02-24 | — | — | US | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-12576026-B2 | Formulations of nebivolol | EXTROVIS AG (CH) | 2026-03-17 | — | — | US | disclosed |
| US-12569434-B2 | Formulations of Nebivolol | EXTROVIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-12466802-B2 | Nebivolol synthesis method and intermediate compound thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2025-11-11 | — | — | US | disclosed |
| EP-4637708-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | Novaliq GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024133913-A9 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2025-03-20 | — | — | WO | disclosed |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (CH) | 2009-02-19 | — | — | US | disclosed |
| WO-2008064826-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008064827-A2 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008040528-A2 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2008-04-10 | — | — | WO | disclosed |
| EP-1803716-A1 | A process for preparation of racemic nebivolol | Cimex Pharma AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| EP-1803715-A1 | A process for preparation of racemic nebivolol | Cimex Pharma AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2007-06-28 | — | — | US | disclosed |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569434-B2 | Formulations of Nebivolol | SI, SORD, SCNN1B | ADRB2 43/4885ADRB1 23/4885HTR1A 4376/4885 |
| US-12466802-B2 | Nebivolol synthesis method and intermediate compound thereof | CYP4A11, CYP11B2, CYP11B1 | ADRB2 5/4885ADRB1 4/4885HTR1A 1267/4885 |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | ADRB1, ADRB2, ADRA2B | ADRB2 2/4885ADRB1 1/4885HTR1A 101/4885 |
| US-20220056003-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, CYP11B1 | ADRB2 5/4885ADRB1 4/4885HTR1A 1267/4885 |
| US-12576026-B2 | Formulations of nebivolol | SI, SORD, SCNN1B | ADRB2 101/4885ADRB1 46/4885HTR1A 4267/4885 |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ADRB1, ADRB2, ADRA2B | ADRB2 2/4885ADRB1 1/4885HTR1A 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.